Mind Medicine (MindMed) Inc. (MNMD) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Vancouver, BC, 加拿大. 现任CEO为 Robert Barrow.
MNMD 拥有 IPO日期为 2016-11-15, 74 名全职员工, 在 NASDAQ Capital Marke, 市值为 $1.56B.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
